Insights › Energy & climate › November 15, 2026
Energy & climate · Pipeline & development

IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors

PR Newswire (Health) Published: Trial

Development candidate demonstrates encouraging preclinical activity in CDKN2A-deficienct tumor models as a monotherapy and in combination with inhibitors of RAS and MTAP, including IDEAYA's proprietary Phase 1 PRMT5 inhibitor IDE892 CDKN2A-deficiency is a common tumor suppressor loss...

Original source
Read the source — prnewswire.com ↗

We link to the original publisher. The summary above is a short guide; read the original for the full details.

More in Energy & climate

See everything in Energy & climate →

Look into this further

Read every record in your own language

This page shows the three newest items per field. Members see every record in the field, in 109 languages, with the search engines that work on them.

Read it all — start from $3No app-store installation. Cancel any time.